Regeneron And Lilly Are Back With Better COVID-19 Antibody Data – But Still Face Medical Skepticism
New Variants Also Make SARS-CoV2 A Moving Target
After disappointing initially, Lilly and Regeneron are back with compelling data for their monoclonal antibody products, but still face challenges from new COVID-19 variants and medical skepticism.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The company is requesting FDA expand the antibody cocktail to include a COVID prevention claim with a lower 1,200mg dose and a subcutaneously administered formula.
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.